Healthcare ETF investors weigh XLV costs against PINK's active mandate
Investors choosing between State Street's XLV and Simplify's PINK must weigh a 43-basis-point fee differential and divergent growth versus income strategies.
A stark divide in fees and management strategies separates the State Street Health Care Select Sector SPDR ETF (XLV) from the Simplify Health Care ETF (PINK). The primary differentiator for cost-conscious market participants is the expense ratio. XLV charges just 0.08%, representing a significant fee advantage over PINK's 0.51% hurdle.
XLV provides a benchmark-driven foundation, tracking the Health Care Select Sector Index since its 1998 launch. The fund holds 60 companies, concentrating almost entirely on healthcare, which comprises 99% of the portfolio. It is heavily weighted toward large-cap pharmaceuticals, led by Eli Lilly at 16.11%, Johnson & Johnson at 10.72%, and AbbVie at 7.79%. Trading near $161.40, the fund yields 1.60%, distributing $2.53 per share over the trailing 12 months to appeal to income-focused buyers.
PINK, launched in 2021, takes a fundamentally different path under active manager Michael Taylor. The fund targets high-growth areas like biotechnology, medical technology, and gene therapy, holding 58 stocks with an 89% healthcare allocation. It maintains smaller positions in industrials and consumer cyclicals to capture adjacent growth. Its top holdings are Thermo Fisher Scientific at 6.98%, Novo Nordisk at 6.87%, and United Therapeutics at 6.79%.
Yielding just 0.60% on a roughly $38.70 share price, PINK distributes $0.25 per share. The fund also employs a currency hedge and distinguishes itself structurally by donating all net profits to the Susan G. Komen foundation. This pro bono mandate has generated $350,000 in contributions as of September 1, 2025.
The decision between these two funds underscores a broader market tension between passive efficiency and active alpha-seeking. XLV’s negligible fee and significantly higher dividend yield make it a straightforward tool for broad sector exposure and consistent cash flow. Conversely, PINK’s higher cost demands scrutiny. Investors must determine if its concentrated growth thesis, portfolio diversification outside pure healthcare, currency hedging, and charitable structure can overcome a fee more than six times higher than the sector standard.
